Immune checkpoint inhibitors: a new frontier in bladder cancer

被引：15
|
作者：
Kates, Max [1 ,2 ]
Sopko, Nikolai A. [1 ,2 ]
Matsui, Hotaka [1 ,2 ]
Drake, Charles G. [1 ,2 ]
Hahn, Noah M. [1 ,2 ]
Bivalacqua, Trinity J. [1 ,2 ]
机构：
[1] Johns Hopkins Sch Med, James Buchanan Brady Urol Inst, 1800 Orleans St,Marburg 420, Baltimore, MD 21287 USA
[2] Johns Hopkins Sch Med, Dept Urol, 1800 Orleans St,Marburg 420, Baltimore, MD 21287 USA
来源：
WORLD JOURNAL OF UROLOGY | 2016年 / 34卷 / 01期
基金：
美国国家卫生研究院;
关键词：
Immune checkpoint; Bladder cancer; Tumor immunology; BACILLUS-CALMETTE-GUERIN; PD-1; BLOCKADE; UROTHELIAL CARCINOMA; ANTI-PD-L1; ANTIBODY; ANTITUMOR IMMUNITY; ADVANCED MELANOMA; IFN-GAMMA; CTLA-4; EXPRESSION; SAFETY;
D O I：
10.1007/s00345-015-1709-y
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Immunotherapy is rapidly changing the field of urologic oncology. In this review, we discuss the role of the immune system in general and place a particular emphasis on the biology of the immune checkpoint and its role in cancer. Bladder cancer, as one of the most immunogenic neoplasms, is an exciting target for immune checkpoint inhibition. Early preclinical data and human trial experience suggest that this new drug class may shape bladder cancer therapy for years to come.
引用
收藏
页码：49 / 55
页数：7
相关论文
共 50 条
  • [21] Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer
    Chhaya, Saachi
    Watts, Isabella
    Ng, Kenrick
    Mustapha, Rami
    Powles, Thomas
    Sharma, Anand
    Vasdev, Nikhil
    [J]. ONCOLOGY AND THERAPY, 2023, 11 (01) : 49 - 64
  • [22] New Settings for Immune Checkpoint Inhibitors in Urothelial Cancer
    Siefker-Radtke, Arlene O.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 629 - 632
  • [23] Immune checkpoint inhibitors: new strategies to checkmate cancer
    Wilson, R. A. M.
    Evans, T. R. J.
    Fraser, A. R.
    Nibbs, R. J. B.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 191 (02): : 133 - 148
  • [24] Immune checkpoint inhibitors: a new era for esophageal cancer
    Zou, Li-Qing
    Yang, Xi
    Li, Yi-Da
    Zhu, Zheng-Fei
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 731 - 738
  • [25] Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer
    Heather Katz
    Emnet Wassie
    Mohamed Alsharedi
    [J]. Medical Oncology, 2017, 34
  • [26] Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer
    Katz, Heather
    Wassie, Emnet
    Alsharedi, Mohamed
    [J]. MEDICAL ONCOLOGY, 2017, 34 (10)
  • [27] Checkpoint Inhibitors for Advanced Bladder Cancer
    Messing, Edward M.
    [J]. BLADDER CANCER, 2016, 2 (04) : 473 - 474
  • [28] Association of CREBBP mutation with favorable outcome with immune checkpoint inhibitors in bladder cancer
    Sheng, W.
    Zhang, Q.
    Duan, Q.
    Tan, Y.
    Sun, T.
    Qi, C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1348 - S1349
  • [29] Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
    Roviello, Giandomenico
    Catalano, Martina
    Santi, Raffaella
    Palmieri, Valeria Emma
    Vannini, Gianmarco
    Galli, Ilaria Camilla
    Buttitta, Eleonora
    Villari, Donata
    Rossi, Virginia
    Nesi, Gabriella
    [J]. CANCERS, 2021, 13 (17)
  • [30] Efficacy of immune checkpoint inhibitors (ICIs) in rare histological variants of bladder cancer
    Philip, Errol James
    Wright, Francis
    Kim, Daniel Myung
    Kwon, Daniel
    Ho, Hansen
    Ho, Son
    Cheung, Edna
    Chan, Emily
    Porten, Sima P.
    Wong, Anthony C.
    Borno, Hala
    Desai, Arpita
    Chou, Jonathan
    Oh, David Yoonsuk
    Aggarwal, Rahul Raj
    Fong, Lawrence
    Small, Eric Jay
    Friedlander, Terence W.
    Koshkin, Vadim S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345